Drug Trial Radar · NCT02256969
Intraductal Meibomian Gland Probing Trial
Last checked: Nov 20, 2026Latest source record: Jun 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Oct 2014
Primary completion
Aug 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- Joseph B. Ciolino, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 6, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this research study, the investigators are looking at the effects of Meibomian Gland Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have already tried traditional management with no success in resolving their clinical signs (as seen by their ophthalmologist) or their symptoms. The investigators are also evaluating the effects of using two (2) post-procedural medication treatments: Blephamide or GenTeal PM Night-Time to determine if treatment after the MGP procedure has an effect on its outcome.
Conditions
- Meibomian Gland Dysfunction
Interventions
BlephamideDrug
GenTeal PM Night-TimeDrug
Meibomian Gland ProbingProcedure
For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
Sham Meibomian Gland ProbingProcedure
For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular Surface Disease Index (OSDI)Time frame: 4 week Time Point
- Symptom Assessment in Dry Eye (SANDE)Time frame: 4 week Time Point
- Corneal Fluorescein Staining (CFS)Time frame: 4 week Time Point
- Tear Break Up Time (TBUT)Time frame: 4 week Time Point
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.